AT-I can downregulate the expression of cyclin-dependent kinases (CDK1) in ovarian cancer SK-OV-3 and ovarian carcinoma (OVCAR)-3 cells through the PI3K/AKT pathway, which leads to cell cycle arrest in the G2/M phase, and plays an important role in the proliferation inhibition of tumor cells [86]. Here, AKT1 is linked to ovarian carcinoma.